Navigation Links
Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
Date:11/2/2009

MOUNTAIN VIEW, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will release results for the quarter ended September 30, 2009 on Monday, November 9, 2009, following the close of the U.S. financial markets. The Company will host an investor conference call at 5:00 p.m. Eastern Time on the same day to discuss these third quarter results. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PNPXXM88G.

To access the live conference call via phone, dial 888-680-0890. International callers may access the live call by dialing 617-213-4857. The reference number to enter the call is 73903374.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 39939108.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... EST on Friday, January 6, 2012 at the Millennium Hotel, ... Executive Officer, Patrick G. LePore, and other members of the ... growth strategy, current products and pipelines, and business outlook to ...
... Calif., Dec. 5, 2011  Beyond Lucid Technologies, Inc., ... disaster management, and First Response industries, today announced ... the mHealth Summit, and the publication of a ... connect ambulances with hospitals via telemedicine. ...
Cached Medicine Technology:Beyond Lucid Technologies Advances Telemedicine for EMS Providers 2Beyond Lucid Technologies Advances Telemedicine for EMS Providers 3
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Mike Day, ... in 2007, will compete in the Ironman World Championships in Kona on October 10th. ... have incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore ...
(Date:9/4/2015)... Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... Program was ranked number 9 nationwide by Doximity. Faculty, residents and staff ... we take great pride in the quality of our ophthalmology residency program. Our faculty ...
(Date:9/4/2015)... ... September 04, 2015 , ... ECC ... first neighborhood created specifically for adults with intellectual, developmental and acquired disabilities. The ... and feature 30 cottage or “pocket” homes. In this community, adults will live ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... comparison to settlements under the Stark physician self-referral law. “Stark Law DOs ... webinar from Atlantic Information Services, Inc. (AIS), will detail which deals are attracting ...
(Date:9/4/2015)... ... September 04, 2015 , ... EMED Jamaica Global Ltd. ... it has entered into a multi-year agreement with Health City Cayman Islands. , ... link between American healthcare, Jamaican healthcare and Health City Cayman Islands to deliver ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6
... maintain significant testosterone levels despite therapy, study ... -- U.S. researchers have uncovered new information ... to androgen-deprivation therapy, which suppresses circulating testosterone, ... , Androgen therapy, which involves the use ...
... recurrences seen in those who had relatives with disease, study ... makeup that increases the risk of developing colorectal cancer also ... new study indicates. , People with colorectal cancer who had ... to die or to have a recurrence after treatment, according ...
... have taken the search for cancer-causing genes an important ... that a gene called DLC1 is a tumor suppressor. ... inactivation or loss precipitates events culminating in an aggressive ... epithelial cancers of the liver (also known as hepatocellular ...
... who drink 100% juice, but not all experts agree with ... drink 100 percent fruit juices apparently don,t tend to be ... who don,t drink the beverages, a new study finds. , ... lead researcher Theresa A. Nicklas, a professor of pediatrics at ...
... China, June 3 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Medical", "CSY"), a manufacturer,marketer and distributor of pharmaceutical, ... that five of its products have,received production permit ... ago, China Sky One Medical began to develop ...
... long wrestled with how to aid those who suffer ... inject an artificial gel that can imitate cartilage,s natural ... that solution is temporary, requiring follow-up injections. , Now ... way to regenerate cartilage naturally by creating a synthetic ...
Cached Medicine News:Health News:Androgen Production Continues in Prostate Cancer Tumors 2Health News:Family History Might Improve Odds Against Colon Cancer 2Health News:CSHL scientists trace causal link between a tumor suppressor gene and liver cancer 2Health News:CSHL scientists trace causal link between a tumor suppressor gene and liver cancer 3Health News:Fruit Juice May Be Healthy for Kids: Study 2Health News:Fruit Juice May Be Healthy for Kids: Study 3Health News:China Sky One Medical, Inc. Receives SFDA Approval for Five Patches 2Health News:China Sky One Medical, Inc. Receives SFDA Approval for Five Patches 3Health News:Brown researchers work toward ending cartilage loss 2
... Requires minimal cervical spine manipulation. Prevent ... or nasally. Cost effective alternative to X-ray. ... of the soft tissues in the neck. ... location of the trachea relative to the ...
... manipulation. Prevent dental and soft tissue damage. ... to X-ray. Light-guided intubation is based upon ... the neck. This technique takes advantage of ... to the esophagus. A well-defined, circumscribed glow ...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
... Aaron manufactures two groups of flexible ... sterile and non-sterile in three different sizes ... flexible shaft portion of the light). These ... additional light is needed., ,The second ...
Medicine Products: